Home › Chronic Pancreatitis › Pennsylvania › Pittsburgh
Chronic Pancreatitis clinical trials in Pittsburgh, PA
6 studies for Chronic Pancreatitis are looking for participants at sites in and around Pittsburgh (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Malabsorption Blood Test (MBT) to Determine Exocrine Pancreatic Function and Related Quality of Life in Chronic Pancreatitis
RecruitingPhase 4
- University of Pittsburgh Medical Center, Pittsburgh
QST Study: Predicting Treatment Response in Chronic Pancreatitis Using Quantitative Sensory Testing
RecruitingHealthy volunteers welcome
- University of Pittsburgh Medical Center, Pittsburgh
Pancreatic Quantitative Sensory Testing (P-QST) to Predict Treatment Response for Pain in Chronic Pancreatitis
Recruiting
- University of Pittsburgh Medical Center, Pittsburgh
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
RecruitingObservational study
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis
RecruitingEarly phase 1
- University of Pittsburgh Medical Center, Pittsburgh
Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes Mellitus
RecruitingPhase 2
- University of Pittsburgh, Pittsburgh
- University of Pittsburgh Medical Center, Pittsburgh
Chronic Pancreatitis trials in other cities
Other studies in Pittsburgh
- Non-Small Cell Lung Cancer48 studies
- Cancer (all types)41 studies
- Breast Cancer39 studies
- Colorectal Cancer32 studies
- Metastatic Cancer31 studies
- Melanoma31 studies
- Ovarian Cancer30 studies
- Endometrial Cancer23 studies
- Prostate Cancer23 studies
- Lung Cancer23 studies
- Head and Neck Squamous Cell Carcinoma22 studies
- Stroke22 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.